# Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>AP</td>
<td>Anteroposterior</td>
</tr>
<tr>
<td>AS</td>
<td>Ankylosing spondylitis</td>
</tr>
<tr>
<td>ASAS</td>
<td>Assessment in ankylosing spondylitis</td>
</tr>
<tr>
<td>BASDAI</td>
<td>Bath Ankylosing Spondylitis Disease Activity Index</td>
</tr>
<tr>
<td>BASFI</td>
<td>Bath Ankylosing Functional Index</td>
</tr>
<tr>
<td>BASRI</td>
<td>Bath Ankylosing Spondylitis Radiology Index</td>
</tr>
<tr>
<td>CRP</td>
<td>C-reactive protein</td>
</tr>
<tr>
<td>DC-ART</td>
<td>Disease-controlling antirheumatic therapy</td>
</tr>
<tr>
<td>DMARD</td>
<td>Disease-modifying antirheumatic drug</td>
</tr>
<tr>
<td>ESR</td>
<td>Erythrocyte sedimentation rate</td>
</tr>
<tr>
<td>FDA</td>
<td>Food and Drug Administration</td>
</tr>
<tr>
<td>HLA-B27</td>
<td>Human leukocyte antigen B27</td>
</tr>
<tr>
<td>ICL</td>
<td>Imaging core laboratory</td>
</tr>
<tr>
<td>IND</td>
<td>Investigational New Drug</td>
</tr>
<tr>
<td>ITT</td>
<td>Intention to treat</td>
</tr>
<tr>
<td>LDAS</td>
<td>Low disease activity state</td>
</tr>
<tr>
<td>LOCF</td>
<td>Last observation carried forward</td>
</tr>
<tr>
<td>MCID</td>
<td>Minimal clinical important difference</td>
</tr>
<tr>
<td>MRI</td>
<td>Magnetic resonance imaging</td>
</tr>
<tr>
<td>NDA</td>
<td>New Drug Application</td>
</tr>
<tr>
<td>NME</td>
<td>New molecular entity</td>
</tr>
<tr>
<td>NRS</td>
<td>Numeric rating scale</td>
</tr>
<tr>
<td>NSAID</td>
<td>Nonsteroidal anti-inflammatory drug</td>
</tr>
<tr>
<td>OA</td>
<td>Osteoarthritis</td>
</tr>
<tr>
<td>RA</td>
<td>Rheumatoid arthritis</td>
</tr>
<tr>
<td>RCT</td>
<td>Randomized controlled trial</td>
</tr>
<tr>
<td>SAARD</td>
<td>Slow-acting antirheumatic drug</td>
</tr>
<tr>
<td>SASSS</td>
<td>Stoke’s Ankylosing Spondylitis Spinal Score</td>
</tr>
<tr>
<td>SD</td>
<td>Standard deviation</td>
</tr>
<tr>
<td>SMARD</td>
<td>Symptom-modifying antirheumatic drug</td>
</tr>
<tr>
<td>TNF</td>
<td>Tumor necrosis factor</td>
</tr>
<tr>
<td>VAS</td>
<td>Visual analog scale</td>
</tr>
</tbody>
</table>
Index

A
Abatacept, 44–45
Abbott Laboratories Ltd., 291
Abbreviations, 309
Abstracts, of journal articles, 172, 174–175, 176, 177
structured, 183
Acetaminophen, as osteoarthritis treatment, 7, 8
Acid phosphatase 5b, tartrate-resistant (TRACP-5b), 154–155
Activity of Daily Living Scale (ADLS), 60
Acute-phase reactants
in ankylosing spondylitis, 76
in rheumatoid arthritis, 62
Adalimumab, 37, 39
cost-effectiveness of, 296
ADAMTS-5, 262, 265
Adhesion molecules, soluble, as inflammation markers, 160
Ad Hoc Working Group for Critical Appraisal of the Medical Literature, 174–175
Adverse drug reactions
emergency hospital admissions for, 285
genetic testing-based prediction of, 285
monitoring of, 130–131
statistical analysis of, 197–198
Adverse events. See Adverse drug reactions
Advertising, for recruitment of clinical trial subjects, 125, 129–130
Advocacy, for clinical trial subjects, 132–133
Aggrecan
biomarkers of, 261–262
chondroitin sulfate (CS) epitope of, 158
in osteoarthritis, 152
Aggrecanases, 262, 265
Aggrecan assays, proteolytic neoepitope-specific, 262, 265
AGIX4207, 42
Alkaline phosphatase, bone-specific, 154
Alzheimer’s disease, 250
American College of Rheumatology (ACR) clinical core set measures of
for rheumatoid arthritis clinical trials, 63–64, 66
as surrogate end points, 171
rheumatoid arthritis remission criteria of, 65
Anakinra, 42–43
Analysis of variance (ANOVA) models, 178
Ankylosing spondylitis
infliximab treatment of, 290, 291
tumor necrosis factor-α antagonist treatment of, 39–40
Ankylosing spondylitis clinical trials assessment of response/improvement in, 77–78
end points in
acute-phase reactants, 76
enthesitis, 76
fatigue, 75
functional capacity, 75
instruments for, 74–77
numerical rating scales (NRS), 74, 75
pain, 75
patient global assessment, 75
peripheral involvement, 76
radiographic assessment, 76–7
spinal mobility, 75–76
spinal stiffness, 75
types of, 73
visual analogue scale-based, 74, 75
study design components, 69–72
duration of follow-up, 70
evaluation and presentation of results, 71–72
handling of missing data, 70–71, 78
Ankylosing spondylitis clinical trials (cont.)
intention-to-treat (ITT) analysis, 70, 72, 78
last observation carried forward (LOCF) technique, 70, 72
randomized controlled trials, 69–70
sample size calculation, 71
trial design, 69–70
Anti-cyclic citrullinated peptides, as rheumatoid arthritis biomarkers, 152, 153–154, 163
Antiflaggrin antibodies, as rheumatoid arthritis biomarkers, 154
Antifolates, as rheumatoid arthritis treatment, 19, 21–22
Antimalarials, as rheumatoid arthritis treatment, 13, 19, 21
Anti-tumor necrosis factor-α therapy. See Tumor necrosis factor-α antagonist therapy
Anti-Tumor Necrosis Factor Therapy in RA with Concomitant Therapy (ATTRACT) study, 297, 298–299, 300–301
ARAMIS study, 297, 300–301
Arthritis Foundation, 16
Arthritis Impact Measurement Scales (AIMS), 59, 60, 180
Arthritis Research Campaign, 16
Arthroscopy, of osteoarthritis-related cartilage damage, 236
Aspergillosis, 40
Assessment in Ankylosing Spondylitis (ASA) Working Group, 73–74, 76–78
Association studies, 277–278
of osteoarthritis, 281
ASSURE trial, 46
ATTRACT (Anti-Tumor Necrosis Factor Therapy in RA with Concomitant Therapy) study, 297, 298–299, 300–301
Audits, of clinical trials, 120–121
documentation of, 127
Auranofin, as rheumatoid arthritis treatment, 21
Azathioprine
as rheumatoid arthritis treatment, 13, 19, 21, 23, 290
toxicity of, 283

B
Bath Ankylosing Spondylitis Functional Index (BASFI), 75, 77
B-cell depletion therapy, 44–45, 66
anti-cyclic citrullinated peptide antibodies in, 154
B cells, in rheumatoid peptide antibodies, 152
Belimumab, 45–46
Belmont report, 101
Beneficence ("do no harm"), 101
Bias, 104, 171, 179
Biochemical markers, of osteoarthritis and rheumatoid arthritis, 151-169. See also specific biochemical markers
of bone turnover
bone formation markers, 154, 155
bone resorption (degradation) markers, 154–156
in rheumatoid arthritis, 62
of cartilage turnover, 151, 156–159
cartilage turnover markers
of cartilage degradation, 156–158
cartilage synthesis or turnover markers, 156, 158–159
concentrations of, 256–257
relationship with tissue turnover, 256–257
definition of, 253–254
of inflammation, 160
measures/assays of analytical considerations in, 160–164
preanalytical considerations in, 164–165
selection of laboratories for, 116
renal and hepatic clearance of, 160, 164–165
role of, 152–153
sample collections of, 114
as surrogate end points, 249–274
type 0, 254, 255
type I, 254, 255
type II, 254, 255
Biological response modifiers, for inflammatory arthritis, 37–49
abatacept, 44–45
anakinra, 42–43
belimumab, 45–46
CAMPATH-1H, 46
cost-effectiveness of, systematic review of, 294–306
ICER ratio in, 297–299, 302, 303–304
search strategy for, 294–295
summary characteristics and quality assessment, 295–299
eculizumab, 46
natalizumab, 46
rituximab, 43–44
tocilizumab, 45
tumor necrosis factor-α antagonists, 37–42
for ankylosing spondylitis, 39–40
economic considerations in, 41
future developments in, 42
for juvenile idiopathic arthritis, 40
for psoriatic arthritis, 40
for rheumatoid arthritis, 37–39
safety considerations in, 40–41

Birmingham Rheumatoid Arthritis Model (BRAM), 295, 297, 299, 300–301, 302, 303–304
Blinding, 95, 172, 176, 179
Blood samples
  genetic testing of, 99
  handling of, 128
Bone density, low, as osteoarthritis progression risk factor, 252
Bone remodelling, in osteoarthritis, 223
Bone turnover, biochemical markers of, 151, 154–156
  bone formation markers, 154
  bone resorption (degradation) markers, 154–156
  in rheumatoid arthritis, 62
BRISK study, 153, 165
British National Formulary (BNF), 290
British Society for Rheumatology (BSR), 40, 41
Budget, for clinical trials, 125–126
C
CAMPATH-1H, 46
Cancer, tumor necrosis factor-α antagonist therapy-related, 41
Cartilage oligomeric matrix protein (COMP), 156–157, 159, 160, 164
definition of, 262
effect of ethnic and sex factors on, 264
meniscal content of, 263
as osteoarthritis biomarker, 262–263
correlation with magnetic resonance imaging findings, 266
in osteoarthritis-related inflammation, 257
synovial content of, 263
as synovitis cause, 263
Cartilage turnover/loss
biochemical markers of, 151, 156–159
cartilage degradation markers, 156–158
cartilage synthesis or turnover markers, 156, 158–159
concentrations of, 256–257
in rheumatoid arthritis, 62
matrix molecular turnover in, 263, 264
osteoarthritis-related, 6–7
surrogate measurement of, 223, 227
water content of, 238
CartilLaps assay, 157
Case report form (CRF), 124–125
Catastrophic cytokine storm, 46
Cathepsin K, 155–156
Cathepsin K gene, homozygous null, 261
Celecoxib, 9
Chemokines, in arthritic disorders, 289
Chest expansion test, for spinal mobility, 75
Chloroquine, as rheumatoid arthritis treatment, 13
Chondroitin, as osteoarthritis treatment, 10–11
Clinical end points, definition of, 254
Clinical trials
  negative, 104
  organization of, at the investigation site, 123–134
  organization of, by the sponsor, 113–122
  biochemical marker assays, 116
couriers, 116
cross-calibration of scanners, 117–118
data flow, 118–119
data monitoring committee, 119–120
investigator meetings, 117
medical imaging, 114–115
regulatory guidance and, 113–114
selection of radiologists, 115–116
subject exclusion/inclusion criteria, 118
surrogate markers, 114–116
trial audit, 120–121
trial closure, 121
COBRA study, 157
Cod liver oil, as osteoarthritis treatment, 11
Collagen degradation products
  as bone resorption biomarkers
    in osteoarthritis, 258–261
    in osteoporosis, 258
  as osteoarthritis biomarkers, 258–264
  as osteoporosis biomarkers, 258
  proteolytic pathways of, 258–259
Collagen type I degradation products,
  155–156. See also C-telopeptide-to-helix (CTx) fragment(s);
    N-telopeptide-to-helix (NTx) fragment(s)
  as bone resorption markers,
    155–156
Collagen type II
as biomarker target, 257
localization of, 257
Collagen type II degradation products
collagenase neoepitope assay for, 263
C-telopeptide-to-helix fragments of. See
C-telopeptide-to-helix-II (CTx-II) fragments
non-joint cartilage origin of, 257
N-telopeptide-to-helix-II (NTx-II) fragments, 260–261
Collagen type III, N-propeptide of (PIIINP), 158, 159, 160
Committee for Proprietary Medicinal Products (CPMP), 91
Compliance, in clinical trial subjects, 132
Computed tomography, scanner calculation for, 117–119
Congestive cardiac failure, 41
Consent form, 111
CONSORT statement, on publication of clinical trials, 172–174, 176, 177
Corticosteroids, as rheumatoid arthritis treatment, 19
Cortisone, as rheumatoid arthritis treatment, 24
Couriers, in clinical trials, 116
C-propeptide (CPII) assay, 158
C-reactive protein (CRP), as biochemical marker
in ankylosing spondylitis, 76
in osteoarthritis, 160, 258
in rheumatoid arthritis, 55, 63, 152, 180
Crohn’s disease, 47
Cross-calibration phantoms, 117–118
Crosslaps (CTx-I) assays, 163
CS-846 assay, 158
C-telopeptide-to-helix (CTx) fragment(s), 154–156, 258
in pycnodysostosis, 261
in rheumatoid arthritis, 62
C-telopeptide-to-helix (CTx) fragment assays, 163
effect of food intake on, 164
proteolytic neoepitopes in, 258–259
C-telopeptide-to-helix-II (CTx-II) fragment(s), 155, 156, 259
as osteoarthritis progression marker, 266
proteolytic epitopes of, 258–260
in pycnodysostosis, 261
in rheumatoid arthritis, 62
urinary effect of risdronate on, 261
as mineral cartilage collagen degradation product, 261
C-telopeptide-to-helix-II (CTx-II) fragments, 157, 158
CTX. See C-telopeptide-to-helix (CTx) fragment(s)
CTX-I. See C-telopeptide-to-helix (CTx) fragment(s)
CTX-II. See C-telopeptide-to-helix-II (CTx-II) fragments
Cyclooxygenase-II inhibitors (COX-II), 13, 14, 17–18
adverse cardiovascular effects of, 66
as osteoarthritis treatment, 9
Cyclophosphamide, as rheumatoid arthritis treatment, 13
Cyclosporin (cyclosporine), as rheumatoid arthritis treatment, 13, 19, 23
Cytokine genes, 282–283, 283–284
Cytokines
anti-inflammatory, 11
proinflammatory, 152, 289, 290
Cytotoxic T-lymphocyte-associated antigen 4 (TLA4), 45
D
DAS index, as rheumatoid arthritis activity measure, 62–63, 66
Data analysis and presentation guidelines, for clinical trials. See Publication guidelines, for clinical trials
Data flow, in clinical trials, 118–119
electronic data capture (EDC), 124–125
Data safety monitoring committees, 119–120, 131
Declaration of Helsinki, 91, 131
Demyelination, tumor necrosis factor- antagonist therapy-related, 41
Deoxypyridinoline, as bone resorption marker, 154–155, 259
Dexamethasone, as rheumatoid arthritis treatment, 24
Diclofenac, 9
Disability, in rheumatoid arthritis, 180
measurement of, 60–61
Disease Activity Score (DAS), 15–16
Disease-modifying antirheumatic drug(s)
combination, 25
cost-effectiveness of, 294–306
slow onset of action of, 289
toxicity of, 289
Disease-modifying anti-rheumatic drug clinical trials
for osteoarthritis, 250
  clinically meaningful outcome in, 255
  subject (patient) selection for, 241
  surrogate markers for, 94
for rheumatoid arthritis
  phase II and III trials, 58
  placebo arm in, 58
  randomized controlled trials, 57
  remission criteria for, 65
  subject (patient) selection for, 56, 241
Dissemination, of clinical trial findings, 104.
  See also Publication guidelines, for clinical trials
DMARDs. See Disease-modifying antirheumatic drug(s)

E
Early Rheumatoid Arthritis Study (ETAS), 298–299, 301
Embrel. See Etanercept
Eculizumab, 46
Editorial review, 100–102
Electronic data capture (EDC), 124–125
End points. See also Surrogate end points
  choice of, 101
  multiple, as cause for exclusion from meta-analyses, 171
Enthesitis, 76
Environmental factors, in osteoarthritis, 281–282
Enzyme-linked immunoassay (ELISA), for biochemical markers, 161, 163
Erythrocyte sedimentation rate (ESR)
  in ankylosing spondylitis, 76
  in rheumatoid arthritis, 55, 62, 180
Etanercept, 37, 38, 40
  cost-effectiveness of, 295, 296, 297, 298, 299, 303–304
Ethical considerations, in clinical trials, 91–111
  blood and tissue sample use and storage, 99–100
  dissemination of trial findings, 104
  editorial review, 100–102
  exclusion/inclusion of subjects, 95–96
  genetic testing of blood samples, 99
  good clinical practice guidelines, 91
  informed consent, 102–103
  placebo use, 93–94
  randomization, 94–95
  recruitment of subjects, 93–95
  regarding sponsors, 92–93
  trial procedures, 96–100
Ethics committees, 126, 127, 139, 180
Etodolac, 9
Etoricoxib, 9
European Clinical Trials Directive, 91, 101–102
European Clinical Trials System, 102
European League Against Rheumatism (EULAR), 63–65
F
Fatigue, ankylosing spondylitis-related, 75
Fibrosis, pulmonary, tumor necrosis factor-α antagonist therapy-related, 41
Food and Drug Administration (FDA), 91
  clinical trial core set measures of, 66
  ethical standards for research on human subjects, 101
  Form 1572, 126–127
  interaction with clinical trial sponsors, 114
  laboratory audits by, 121
Frozen samples, 128
Functional Status Index (FSI), 60
G
Gene therapy, 100
Genetic counseling, 99
Genetic profiling, 100, 284–285
Genetics/genomics, in osteoarthritis and rheumatoid arthritis, 275–287
  gene identification methods and animal linkage studies, 278–279
  association studies, 276, 277–278
  linkage analysis, 276–277
  nonparametric linkage analysis, 277
  transmission disequilibrium test (TDT), 278
  genetic determinants in osteoarthritis, 281–282
  in rheumatoid arthritis, 282–283
  microarrays and proteomics, 279–280
  pharmacogenetics, 279–280, 283–285
Genetic testing, of blood samples, 99
Gene transfer-based therapy, for osteoarthritis, 11
Glucocorticoid intra-articular injections as osteoarthritis treatment, 10
  as rheumatoid arthritis treatment, 24–25
Glucocorticoids
  adverse effects of, 24
  as rheumatoid arthritis treatment, 18, 23–25
Glucosamine and chondroitin, as osteoarthritis treatment, 10–11
Glucosamine sulfate, 233
Glucosyl-galactosyl pyridinoline (GGP), 159
Glycosaminoglycans, osteoarthritis-related loss of, 6
Gold salts therapy, for rheumatoid arthritis, 13, 19, 22–23
Golimumab, 42
Good clinical practice (GCP) guidelines, 91, 113
clinical laboratory report review, 130–131

H
Hand
osteoarthritis of
American College of Rheumatology clinical trial criteria for, 85
genetic factors in, 281
severity grading of, 230
rheumatoid arthritis of, 55
Haplotype Mapping Project, 275, 278
Health Assessment Questionnaire (HAQ), 59, 60, 180
as quality-adjusted life years (QALYs) predictor, 297
use in cost-effectiveness studies, 297, 298–299, 302
Health economics
cost-benefit analysis (CBA), 291
cost-effectiveness analysis (CEA), 291–292
of biological response modifiers, 289–307
cost-utility analysis (CUA), 292
economic modeling, 292–294
opportunity cost, 290–291
randomized controlled trials and, 292
Health outcome measures, in rheumatoid arthritis, 61–62
Heberden’s nodes, 6
Hip, osteoarthritis of
American College of Rheumatology clinical trial criteria for, 85
genetic factors in, 281
joint space width changes in, 88
severity grading of, 230
Hip replacement, as osteoarthritis treatment, 11–12
Histoplasmosis, 40
HLA-DR gene, in rheumatoid arthritis, 282
Homocysteine, 20
Homunculus (mannequin), for recording joint involvement, 61
Human cartilage glycoprotein-39, 156–157, 158
Human Genome Project, 275
Humira. See Adalimumab
Hyaluronan, in osteoarthritis, 257
Hyaluronic acid
osteoarthritis-related loss of, 6
as osteoarthritis treatment, 10
as synovitis marker, 159
Hydrocortisone, as rheumatoid arthritis treatment, 24
Hydroxychloroquine, as rheumatoid arthritis treatment, 19, 21, 25

I
Ibuprofen, 9, 10
ICTP assays, 156
Imaging, in clinical trials. See also Computed tomography (CT); Magnetic resonance imaging (MRI)
organization of, 114–115
Imaging core laboratories (ICLs), 135–150
audits of, 120–121
as central data repositories, 119
evaluation of, 115
FDA guidelines for, 135, 136–139, 142–143, 144, 147–148, 149
roles of, 114–115, 136
do-co-development of the imaging review charter, 136, 138–139
digitalization and processing of radiographs, 143–144
image collection, 142
image database submission, 147–148
image quality control, 142–143
imagery study kit, 140–141
independent review of image data, 144–147, 148
investigator meetings, 139–140
protocol development, 136, 138
radiographic acquisition, 141
sample image data, 141
site survey, 140
standardization of image acquisition, 136, 139–142
subject (patient) selection, 118
training, 140
selection of, 115–116
standard operating procedures (SOPs) of, 115–116
Immunosuppressive agents, as rheumatoid arthritis treatment, 290
Incremental cost-effectiveness ratio (ICER), 297–299, 302, 303–304
Indomethacin, 9, 13
Inflammation
  biochemical markers of, 160
  effect on joint cartilage biomarker concentration, 256–257
  role in osteoarthritis pathogenesis, 258
Inflammatory bowel disease, ankylosing spondylitis-related, 73
Infliximab, 37, 38–39, 40
  adverse effects of, 38, 41
  cost-effectiveness of, 296, 298–299, 300–301, 302, 303–304, 305
  use in children/adolescents, 40
Informed consent, 101, 102–103, 131–132
  regarding radiation exposure, 96
Institutional review boards/independent ethics committees (IRB/IEC), 126, 127, 139
  ethical review by, 100–102
  investigational site approval by, 92
  responsibilities of, 91
  trial procedures and, 96
  trial subjects and, 96
Institutional review boards (IRBs), 180
Intention-to-treat (ITT) analysis, 70, 72, 78, 88–89, 178
Interleukin(s), as inflammation marker, 160
Interleukin-1, in rheumatoid arthritis, 42
Interleukin-1 antagonists, 42–43
Interleukin-1 gene cluster, 281, 282–283
Interleukin-1 receptor gene polymorphisms, 281
Interleukin-1 signaling pathway-blocking agents, 282–283
Interleukin-4 receptor polymorphisms, 281
Interleukin-6 receptors, monoclonal antibodies to, 46
Interleukin-10 gene polymorphisms, 2382–2384
Interleukin-12, monoclonal antibodies to, 46
Interleukin-15, monoclonal antibodies to, 46
International Committee for Harmonization (ICH), 91
Internet, Web-conferencing on, 117
Investigational site, clinical trial organization at, 123–134
  case report form (CRF) completion, 124–125
  clinical trial agreement, 126
  documentation review and storage, 133
  handling and storage of clinical supplies, 129
  handling of blood samples, 128
  informed consent, 126, 131–132
institutional review boards and ethics committees, 126, 127, 139
investigators’ meetings, 127
monitoring of adverse events, 130–131
patient recruitment methods, 129–130
pharmacy, 129
protocols, 127
role of principal investigators in, 123, 124, 126, 128
role of study site coordinators (SCCs) in, 123–125, 126, 128, 132–133
site resources, 124–125
staffing, 124, 125, 215
study budget, 125–126
study closeout, 133
study initiation and conduct, 127
Investigator meetings, 117
ISIS-104838, 42

J
Joint counts, in rheumatoid arthritis, 60
Joint prostheses, for rheumatoid arthritis patients, 25
Joint replacement
  in osteoarthritis patients, 11–12
  in rheumatoid arthritis patients, 25, 26
Joint space narrowing, in osteoarthritis glucosamine sulfate-related inhibition of, 233
  grading of, 228
  radiography of, 232–233
  as surrogate measurement of cartilage loss, 223, 227
Justice, in clinical research, 101
Juvenile arthritis
  chronic, etanercept treatment of, 290, 291
  idiopathic, tumor necrosis factor-α antagonist therapy for, 40

K
Keitel Index, 60
Knee, normal, radiographic appearance of, 229
Knee osteoarthritis
  C-telopeptide-to-helix-II biomarker of, 165
  genetic factors in, 281
  joint space narrowing in, 258
  joint space width changes in, 88
  moderate lateral, 231
  patellofemoral, severity grading of, 231
  radiographic progression of, 153
  severe lateral, 231
  tibiofemoral, severity grading of, 230
Knee osteoarthritis clinical trials
American College of Rheumatology
clinical criteria for, 85
cartilage damage progression in
joint space narrowing (JSN) measure of, 235, 242–243, 258
joint space width (JSW) measure of, 88, 235–236, 242
magnetic resonance imaging of, 235–248
serial radiographs of, 235–236
quantitative magnetic resonance imaging in, 235–248
of articular cartilage volume loss, 257
of cartilage damage progression, 235–248
clinical practice for, 236–238
comparison with standardized knee radiographs, 242–243
cross-sectional cartilage measurements, 241
delayed gadolinium-enhanced, 238
as diffusion tensor imaging (DTI), 238
in longitudinal studies, 241–242
of meniscal damage, 243–244, 245
precision and reliability of, 239–240
radiograph acquisition in, 224–227
fixed-flexion posteroanterior view, 224, 225
fluoroscopic-guided Lyon Schuss view, 224, 225–226
fluoroscopic-guided semiflexed anteroposterior view, 224, 225–226
semiflexed metatarsophalangeal view, 224, 226
standing anteroposterior view, 224, 225
radiography in, 232–233
of risdronate, 261
Knee replacement, as osteoarthritis treatment, 11, 12
Kruskal-Wallis test, 178

L
Laboratories. See also Imaging core laboratories (ICLs)
for blood and urine sampling
accreditation of, 120
audits of, 120, 121
courier services of, 116
Last observation carried forward (LOCF) technique, 70, 72
Lateral spinal flexion test, 76
Lee Index, 60

M
Magnetic resonance imaging (MRI)
of knee osteoarthritis cartilage damage, 235–248
of articular cartilage volume loss, 257
of cartilage damage progression, 235–248
clinical practice for, 236–238
comparison with standardized knee radiographs, 242–243
cross-sectional cartilage measurements, 241
delayed gadolinium-enhanced, 238
as diffusion tensor imaging (DTI), 238
in longitudinal studies, 241–242
of meniscal damage, 243–244, 245
precision and reliability of, 239–240
as outcome measure, in osteoarthritis, 88
in phase II studies, scanner calculation for, 117–119
for sacroiliitis diagnosis, 73
Mallya/Mace index, as rheumatoid arthritis activity measure, 63
Markov models, of biologic response modifier cost-effectiveness, 298, 299
Matrix metalloproteinase(s), 6–7, 152
as aggrecan turnover markers, 262
Matrix metalloproteinase-1, in synovitis, 257–258
Matrix metalloproteinase-3, 257–258, 266
Matrix metalloproteinase inhibitors, 7
McMaster-Toronto Arthritis Scale (MACTAR), 60
Meloxicam, 9
Meta-analyses, exclusion of clinical trials from, 171
Metalloproteinases. See also Matrix metalloproteinase(s)
in osteoarthritis, 152
in rheumatoid arthritis, 156
Methotrexate
cost-effectiveness of, 93–94, 297, 298, 300, 303–304
as rheumatoid arthritis treatment, 13, 19–20, 25
Methylprednisone, as rheumatoid arthritis treatment, 24–25
Microarrays, 279–280
Minocycline, as rheumatoid arthritis treatment, 23
Missing values, 178–179
Modified Schober test, 75–76
Monoclonal antibodies
to interleukin-12, 46
to interleukin-15, 46
to interleukin-6 receptors, 46
to selective adhesion molecule (SAM) alpha 4 integrin, 47
to tumor necrosis factor, 42
Morning stiffness, rheumatoid arthritis-related, 12, 55
as clinical trial end point, 60
duration of, 60
Multiple joints, rheumatoid arthritis of, 55
Multiple sclerosis, 47

N
Naproxen, 9
Natalizumab, 46
National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, 101
National Institute for Clinical Excellence (NICE), 292
Nonrandomized studies, 95
Nonsteroidal anti-inflammatory drug(s)
as cyclooxygenase-2 inhibitors, 9
as osteoarthritis treatment, 9, 289
as rheumatoid arthritis treatment, 18, 289
side effects of, 15, 18
Nonsteroidal anti-inflammatory drug clinical trials
in ankylosing spondylitis, 70
in osteoarthritis, 83
for rheumatoid arthritis, 56, 57, 58
N-propeptide assays, 155, 158, 263
NSAIDs. See Nonsteroidal anti-inflammatory drug(s)
N-telopeptide-to-helix-II (NTx-II) fragments, 260–261
N-telopeptide-to-helix (NTx) fragment(s), 258 in pycnodysostosis, 261
N-telopeptide-to-helix (NTx) fragment assays, 163
effect of food intake on, 164
proteolytic neoepitopes in, 258–259
Nurses, as study site coordinators (SCCs), 123

O
Obesity, as osteoarthritis risk factor, 252, 282
Occiput-to-wall test, 76
Occupational factors, in osteoarthritis, 281–282
Office of Human Research Protection, 102
OMERACT. See Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT)
Osteoarthritis
age factors in, 249–250
aging-related prevalence of, 249
articular damage in, 152
definition of, 5
as disability cause, 249
environmental factors in, 281–282
genetic factors in, 281–282
high-risk patient profile for, 252–253
historical aspects of, 6
idiopathic, 6
inflammation associated with, 281
initiation of, 251
joint space narrowing in, grading of, 228
metalloproteinases in, 152
pain associated with, 250–251
pathogenesis of, 6–7, 152, 251
pathologic features of, 250, 255–256
posttraumatic, 6
prevalence of, 5
radiographic, 281
progression of, 251–252
biomarkers of, 266
risk factors for, 5, 6
signs and symptoms of, 5, 7
treatment of, 7–11, 7–12
analgesics, 7–8, 9–10
disease-modifying antirheumatic drugs, 94, 241, 250, 255
experimental, 11
glucosamine and chondroitin, 10–11
inadequacy of, 250
intra-articular injections, 10
narcotic analgesics, 9–10
non-pharmacological interventions, 7
nonsteroidal anti-inflammatory drugs, 8, 9
suggested protocol for, 8
Osteoarthritis (cont.)
surgical, 11–12, 250
topical analgesia, 9
treatment response biomarkers in, 266
type II collagen in, 152
Osteoarthritis clinical trials
American College of Rheumatology
clinical criteria for, 85
biochemical markers in, 151–169
aggrecan, 152
of cartilage synthesis of turnover, 158–159
potential uses of, 265
role of, 153
as surrogate end points, 249–274
type 0, 265
use in drug development, 267
biochemical marker surrogate end points in, 249–274
of aggrecan degradation and turnover, 152, 261–262
barriers to validation of, 267–268
collagen degradation studies of, 258–261
definitions and classification of, 253–255
factors affecting, 264–265
identification of sources of, 263–264
inflammation and, 257–258
need for, 249–253
neoepitope-related specificity, 258
new, identification of, 268–269
potential uses of, 265–266
relationship with tissue turnover, 256–257
status of, 255–265
magnetic resonance imaging in, 250
for severity grading, 266
outcome measures for, 253
phase III, cost of, 93
radiography in, 223–234
acquisition of radiographs, 224–227
for grading of disease severity, 228–232, 265–266
of joint space narrowing, 232–233
joint space width measurement, 227–228
limitations to, 253
quantitative methods, 223
radiographic changes, 250
semi-quantitative methods, 223, 228–232
severity grading in, 228–232
atlases for, 230
inter-observer and intra-observer variability, 229, 231–232
with Kellgren and Lawrence radiographic changes, 265–266
magnetic resonance imaging-based, 266
surrogate outcome measures in, 253
trial design and outcomes in, 81–90
compliance, 88
control arm, 84, 86
double-blind comparator trials, 81
factorial design, 82
Kellgren and Lawrence osteoarthritis grading system, 83–84
outcome assessment, 86–88
presentation and dissemination, 89
randomized controlled trials, 81–82
sample size, 86
scientific versus pragmatic trials, 82–83
statistics, 88–89
study design, 81–82
study duration, 83
study organization, 89
subject (patient) selection, 83–84, 252
visual analogue pain scales in, 181
x-ray grading system for, 6
Osteoarthritis Initiative, 266
Osteocalcin, as bone formation marker, 154, 155
Osteophytes, 223, 250
Osteoporosis
biomarker assay for, 267
glucocorticoid-related, 24
Outcome measures, in osteoarthritis and rheumatoid arthritis, 180–181
Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT), 86, 87
Core Data Set of, 66
rheumatoid arthritis clinical trial end point measures of, 63
rheumatoid arthritis remission criteria of, 65

P
Pain, as clinical trial end point
in ankylosing spondylitis, 75
in rheumatoid arthritis, 59, 180
Pain scales. See also Visual analog pain scales for rheumatoid arthritis, 59
Paracetamol, as osteoarthritis treatment, 7, 8
Parecoxib, 9
Patient Elicitation Form (PEF), 60
Patient positioning, for imaging studies, 142
Peer-review system, abuse of, 104
Pegsnercept, 42
D-Penicillamine, 13, 19, 23
Pharmacogenetics, 279–280, 283–285
in arthritis treatment, 283–284
in clinical trials, 284–285
Phenylbutazone, 13
Piroxicam, 9
Placebo use, 93–94
Pneumocystis carinii infections, 40
Prednisone, as rheumatoid arthritis treatment, 24
Pregnancy, rheumatoid arthritis treatment during, 20, 21–22
Primary care physicians, role in recruitment of clinical trial subjects, 129
Principal investigators, responsibilities of, 92
Procollagen type I C-propeptide (PICP) fragments of, 154–155
N-propeptide (PINP) fragments of, 154–155
Procollagen type II C-propeptide (PIICP) fragments of, 158
N-propeptide (PIINP) fragments of, of, 159, 160
Procollagen type III, N-propeptide (PIIINP) fragments of, 159, 160
Progressive multiple leukoencephalopathy, 47
Prostheses, for hip or knee osteoarthritis replacement, 11–12
Proteomics, 279–280
Proton pump inhibitors, 18
Psoriasis, ankylosing spondylitis-related, 73
Psoriatic arthritis, treatment of etanercept, 290, 291
infliximab, 290, 291
tumor necrosis factor-α antagonist therapy for, 40
Publication guidelines, for clinical trials, 171–199
abstract, 172, 174–175, 176, 177
structured, 183
bias, 104
comment, 173, 176
conclusions, 198
CONSORT statement on, 172–174, 176, 177
patient flowchart, 182
ethical considerations, 104
introduction, 175, 176
methodology, 172, 176, 177–180
bias, 171, 179
blinding, 172, 176, 179
ethical considerations, 180
missing values, 178–179
protocol, 172, 176
randomization, 179
statistical analysis, 177–178, 182–197
study design, 177
outcome measures and, 180–181
patient flowchart, 172, 173–174, 176
results, 172–173, 176
baseline comparisons, 182
continuous variables, 182–184
control and treatment groups, 182
core set measures, 182
normality of data tests, 182–184
problems with presentation, 181–199
Sharp score, 181, 182
title, 172, 174, 176
Pycnodysostosis, 261
Pyridinoline, as bone resorption marker, 154–155, 258, 259

Q
Quality-adjusted life years (QALYs), 16
as drug cost-effectiveness outcome measure, 292, 295, 296, 297, 299, 302, 303–304, 305
Quality assurance centers, cost-effectiveness of, 114

R
RA Disease Activity Index (RADAI), 62
Radiation exposure, in clinical trials subjects, 96, 98–99
Radiologists, selection of, 115–116
Randomization, 179
as ethical consideration, 94–95
Randomized controlled trials (RCT) bias and, 94
as economic evaluation data source, 29
pharmacogenetic, 279
phase III, study population in, 95
REFLEX trial, of rituximab, 44
Regulatory guidelines, clinical trials, 113–114
Remicade. See Infliximab
Respiratory tract infections, tumor necrosis factor-α antagonist therapy-related, 41
Rest, as rheumatoid arthritis treatment, 17
Rheumatoid arthritis age factors in, 282
autoantibodies in, 152, 153–154
Rheumatoid arthritis (cont.)
- as autoimmune disease, 152
- bone resorption process in, 156
- definition of, 12, 41
- economic costs of, 289
- extra-articular manifestations of, 15, 152
- genetic factors in, 282–283
- joint destruction in, 152, 153
- joint involvement determination in, 153
- metalloproteinases in, 152, 156
- ongoing assessment of, 15–16
- pathogenesis of, 152
- pathophysiology of, 12–13
- patient education about, 16
- prediction of progression of, 155
- pro-inflammatory cytokines in, 152
- quality-of-life assessment of, 15, 16
- radiographic changes in, 55
- remission in, 13
- assessment of, 16
- signs and symptoms of, 12–13
- symmetric, 55
- treatment of, 17–25, 1313
- aggressive, 15
- analgesics, 13
- B-cell depletion-based, 44–45
- biologic response modifiers, 93–94, 294–306
- disease-modifying anti-rheumatic drugs (DMARDs), 13, 17–19, 51, 57, 58, 65
- early initiation of, 14, 15
- evolutionary history of, 13–14
- interleukin-1, 42–43
- nonpharmacological, 16–17
- nonsteroidal anti-inflammatory drugs, 13, 17–18
- renotoxicity/hepatotoxicity of, 15
- surgical, 25–26
- symptom-modifying drugs, 51
- tumor necrosis factor-α antagonists, 37–39
- as work-disability cause, 289

Rheumatoid Arthritis Disease Activity Index (RADAI), 62

Rheumatoid arthritis clinical trials
- American College of Rheumatology classification criteria for, 55, 153–154
- American College of Rheumatology Definition of Improvement in (ACR20), 180–181

biochemical markers for, 151–169

anti-cyclic citrullinated peptide (CCP) antibodies, 152–154
antiflaggrin antibody, 154
antikeratin antibody (AKA), 154
antinuclear antibody, 152
anti-perinuclear factor (APF), 154
autoantibodies, 152–153, 153–154
B cell count, 152
of cartilage synthesis of turnover, 158–159
complement levels, 152
C-reactive peptide, 152
erthrocyte sedimentation rate, 152
immunoglobulin levels, 152
rheumatoid factor, 153–154
role of, 152–153
T cell count, 152
of biological response modifiers
cost-effectiveness studies, 294–306
sample size in, 93–94
clinical improvement criteria for, 16
end points for
- clinical end points, 59–62
- composite measures, 62–66
- core set, 66
- current disease activity, 62–63
- functional/disability, 60–62
- global disease activity, 60
- health outcome measures, 61–62
- imaging end points, 62
- impairment measures, 60
- improvement criteria, 63–65
- indices of disease activity, 62
- joint counts, 60
- laboratory assessment measures, 62
- morning stiffness, 60
- pain, 59
- remission criteria, 65
- single end points, 59–62

phase III
cost of, 93
duration of, 115
imaging core laboratories in, 115
radiographic imaging end points in, 201–222
analyzing and reporting of scores, 219–220
comparison of radiograph scoring methods, 214
Kaye Scoring Method, 207, 210, 211
Kellgren’s Method, 203
Larsen Scoring Method, 205, 206
Larsens’ 1995 modification, 210, 212
Modified Genant Scoring Method, 212, 217
Modified Larsen Score according to Rau and Herborn, 210, 214–215, 216
Modified Sharp Scoring Method, 207, 209
radiographic acquisition and, 201–203
Ratingen Score, 212, 218
reviewing of radiographs, 215–216, 219
scoring methods, 203–214
scoring radiographs for repair, 219
Scott and Larsen Scoring Method, 210, 214
Sharp and van der Heijde Scoring Method, 207–208, 210, 212–213
Sharp Scoring Method, 204–205
Short Erosion Score, 214
Simple Erosion Narrowing Score, 212–214, 219
Steinbrocker Index, 203
regulatory guidelines for, 113–114
study design and end points for, 51–67
case-controlled studies, 57
cohort studies, 57
core domains and subdomains, 52
core variables, 54
cross-over trials, 57–58
cross-sectional trials, 56, 57
definition of outcome, 51
definition of outcome, 51
definition of outcome, 51
end points, 58–66
factorial design, 57
longitudinal trials, 52–53, 56, 57–58
OMERACT IV recommendations for, 53
patient selection, 55–56
Phase I, 58
Phase II, 58
Phase III, 58
Phase IV, 58
potentially important variables, 54
randomized controlled trials, 57
types of clinical trials, 56–58
surrogate end points in, 114
visual analogue pain scales in, 180, 181
Rheumatoid factor, 55, 152–153, 154
Rheumatoid nodules, 55
Risedronate, 165
Rituximab, 43–44, 154
Sample size choice of, 101
small, 171
Scanners, cross-calibration of, 117–118
Schering-Plough, 291
Selective adhesion molecule (SAM) alpha 4 integrin monoclonal antibodies, 47
Self-report questionnaires, of disability, 60
Shapiro-Francia W' test, 178
Sharp score ANOVA of, 190, 191, 192–193, 195
baseline differences testing of, 188
histogram of, 184, 185
normal score plot of, 184
percentage changes in, 188–189
Simplified Disease Activity Index (SDAI), for rheumatoid arthritis, 63, 65
Single-nucleotide polymorphisms (SNPs), 277–278
Site management organizations (SMOs), 92
Spinal mobility assessment, in ankylosing spondylitis, 75–76
Spinal stiffness, in ankylosing spondylitis, 75
Sponsors, of clinical trials. See also Clinical trials, organization of, by the sponsor responsibilities of, 92
Statistical analysis, 188–193
in adverse event monitoring, 197–198
analysis of covariance, 190
analysis of variance (ANOVA), 189–193
as test for baseline differences, 185–187, 188
interaction effect, 190
Kruska-Wallis test, 196
kurtosis, 182, 183
log transformations, 184–185, 187
multiple t-test, 185–187
nonparametric statistics, 184, 188, 193–196
normality of data tests, 182–184
range tests, 185–187
Shapiro-Francia W' test, 183–184
skewness, 182–183, 184
square transformations, 184–185
of treatment effect, 189, 196–197
Wilcoxon rank sum test, 193, 195–196
Stoke Ankylosing Spondylitis Spine Score (SASSS), 77
Stoke index, as rheumatoid arthritis activity measure, 63
Stroke in rheumatoid arthritis patients, 17
Study site coordinators (SCCs), 123–124

S
Sacroiliitis, radiographic, 72, 73
Salicyclic acid, 13
Index

Subjects, in clinical trials
advocacy for, 132–133
exclusion/inclusion criteria for, 95–96, 118
informed consent from, 131–132
motivation for participation, 123
radiation exposure in, 96, 98–99
recruitment of, 125, 129–130
bias in, 130
competitive, 92–94
financial aspects of, 92–93
inappropriate, 92–93
in less-developed countries, 93, 94
into multiple studies, 101
for rheumatoid arthritis clinical trials, 55–56
retention and compliance of, 132

Substance E (hydrocortisone), 13, 23
Sulfasalazine, as rheumatoid arthritis
treatment, 13, 19, 21–22, 25
Surrogate end points
biochemical markers as, 249–274
strengths and limitations of, 255–265
as cause for exclusion from
meta-analyses, 171
definition of, 254
imaging-related blinding in, 95

Synovitis
biochemical markers of, 158, 159
glucocorticoid therapy discontinuation-related, 23
osteoarthritis-related, 255, 256
rheumatoid arthritis-related, 12–13, 255

T
t cells, in rheumatoid arthritis pathogenesis,
45, 152
T-cell-targeted therapies, 290. See also
Alefacept; Efalizumab
TEMPO study, 181, 189
Testosterone, as osteoarthritis progression risk factor, 252
Thiopurine methyl transferase (TPMT), 283
Tocilizumab, 45
Training CDs, for clinical trial technologists, 117
Tramadol, 9–10
Transforming growth factor-β gene
polymorphisms, 283–284
Transmission disequilibrium test (TDT), 278

Trauma, as osteoarthritis predisposing factor,
281–282
Triamcinolone
as osteoarthritis treatment, 10
as rheumatoid arthritis treatment, 24
Tuberculosis, tumor necrosis factor-α
antagonist-related reactivation of, 40–41
Tumor necrosis factor-α
as inflammation marker, 160
in rheumatoid arthritis pathogenesis, 290
Tumor necrosis factor-α antagonist
therapy, 37–42, 66, 290. See
also Adalimumab; Etanercept;
Infliximab
for ankylosing spondylitis, 39–40, 70
cost-effectiveness of, 294–306
economic considerations in, 41
future developments in, 42
for juvenile idiopathic arthritis, 40
for psoriatic arthritis, 40
for rheumatoid arthritis, 37–39,
282–283
cytokine gene polymorphisms and,
283–284
safety considerations in, 40–41
Tumor necrosis factor-α antisense
inhibitors, 42
Tumor necrosis factor gene, 282
polymorphisms of, 283–284
2B4 assay, 259, 260–261

U
United Kingdom
biologic response modifier cost-effectiveness study in, 294–306
clinical trial subject recruitment regulations
in, 129
National Institute for Clinical Excellence
(NICE), 292
rheumatoid arthritis-related health care
costs in, 289
tumor necrosis factor-α blockade therapy
eligibility criteria in, 41
Urine samples, handling of, 128

V
Visual analog pain scales, 59
histograms
log-transformed, 187
with skewed distribution,
184–185, 186
for rheumatoid arthritis, 180, 181
<table>
<thead>
<tr>
<th>Index</th>
<th>325</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vitamin deficiencies, as osteoarthritis progression risk factor, 252</td>
<td>World Health Organization/ilar, 63, 66</td>
</tr>
<tr>
<td>Wyeth Europe Ltd., 291</td>
<td>X</td>
</tr>
<tr>
<td>Warfarin, interaction with analgesics, 8</td>
<td>YKL-40, 156, 159, 160</td>
</tr>
<tr>
<td>Web-conferencing, 117</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>W</th>
</tr>
</thead>
<tbody>
<tr>
<td>Warfarin, interaction with analgesics, 8</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>X</th>
</tr>
</thead>
<tbody>
<tr>
<td>YKL-40, 156, 159, 160</td>
</tr>
</tbody>
</table>